Biogen Inc.

SWX:BIIB Stock Report

Market Cap: CHF 21.4b

Biogen Valuation

Is BIIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 418.76
Fair Value
56.4% undervalued intrinsic discount
29
Number of Analysts

Below Fair Value: BIIB (CHF182.75) is trading below our estimate of fair value (CHF418.76)

Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIB?

Key metric: As BIIB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIIB. This is calculated by dividing BIIB's market cap by their current earnings.
What is BIIB's PE Ratio?
PE Ratio16.5x
EarningsUS$1.61b
Market CapUS$26.60b

Price to Earnings Ratio vs Peers

How does BIIB's PE Ratio compare to its peers?

The above table shows the PE ratio for BIIB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average81.9x
BSLN Basilea Pharmaceutica
8.9x-24.69%CHF 643.9m
SDZ Sandoz Group
138.3x29.12%CHF 25.4b
GALD Galderma Group
127.9x31.48%CHF 39.1b
LONN Lonza Group
52.6x20.44%CHF 38.5b
BIIB Biogen
16.5x8.07%CHF 26.6b

Price-To-Earnings vs Peers: BIIB is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (81x).

Price to Earnings Ratio vs Industry

How does BIIB's PE Ratio compare vs other companies in the European Biotechs Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BIIB 16.5xIndustry Avg. 16.7xNo. of Companies8PE020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIIB is good value based on its Price-To-Earnings Ratio (16.5x) compared to the European Biotechs industry average (16.7x).

Price to Earnings Ratio vs Fair Ratio

What is BIIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIIB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIIB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 182.75
CHF 143.76
-21.34%
18.72%CHF 209.09CHF 104.55n/a29
Dec ’26n/a
CHF 143.87
0%
18.72%CHF 209.26CHF 104.63n/a29
Nov ’26n/a
CHF 140.37
0%
19.94%CHF 209.21CHF 94.95n/a29
Oct ’26n/a
CHF 136.07
0%
22.32%CHF 207.22CHF 94.05n/a29
Sep ’26n/a
CHF 135.58
0%
23.11%CHF 208.04CHF 94.42n/a28
Aug ’26n/a
CHF 136.63
0%
23.56%CHF 209.32CHF 92.59n/a30
Jul ’26n/a
CHF 137.73
0%
23.87%CHF 207.95CHF 91.98n/a31
Jun ’26n/a
CHF 141.53
0%
23.77%CHF 214.01CHF 94.66n/a31
May ’26n/a
CHF 148.84
0%
26.99%CHF 248.87CHF 95.40n/a30
Apr ’26n/a
CHF 176.42
0%
28.64%CHF 301.50CHF 119.01n/a30
Mar ’26n/a
CHF 181.63
0%
28.19%CHF 308.76CHF 121.88n/a30
Feb ’26n/a
CHF 207.20
0%
24.77%CHF 310.35CHF 125.23n/a29
Jan ’26n/a
CHF 220.05
0%
22.10%CHF 307.93CHF 147.66n/a29
Dec ’25n/a
CHF 223.89
0%
17.78%CHF 301.12CHF 162.00n/a29
Nov ’25n/a
CHF 222.59
0%
16.80%CHF 297.75CHF 156.71n/a30
Oct ’25n/a
CHF 228.64
0%
13.67%CHF 289.41CHF 160.78n/a30
Sep ’25n/a
CHF 231.31
0%
12.99%CHF 291.46CHF 161.92n/a30
Aug ’25n/a
CHF 243.23
0%
13.57%CHF 305.77CHF 174.72n/a30
Jul ’25CHF 222.00
CHF 253.28
+14.09%
14.43%CHF 313.08CHF 178.90n/a30
Jun ’25CHF 222.00
CHF 260.15
+17.18%
14.23%CHF 319.73CHF 182.70n/a29
May ’25CHF 222.00
CHF 263.04
+18.49%
13.39%CHF 321.70CHF 183.83n/a31
Apr ’25CHF 222.00
CHF 264.76
+19.26%
12.66%CHF 352.46CHF 202.67n/a30
Mar ’25CHF 222.00
CHF 264.76
+19.26%
12.66%CHF 352.46CHF 202.67n/a30
Feb ’25CHF 222.00
CHF 269.62
+21.45%
11.11%CHF 349.72CHF 211.04n/a30
Jan ’25CHF 222.00
CHF 267.45
+20.47%
10.24%CHF 337.08CHF 204.47n/a31
Dec ’24CHF 222.00
CHF 287.27
+29.40%
11.05%CHF 355.55CHF 215.67n/a29
CHF 180.19
Fair Value
1.4% overvalued intrinsic discount
29
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/08 14:46
End of Day Share Price 2025/12/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biogen Inc. is covered by 62 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays